

Regd. Office :

'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com

November 6, 2014

Bombay stock Exchange Limited
1st Floor, P.J. Towers
Dalal Street
MUMBAI – 400 001

Kind Attn.: Mr. Kapoor
Mr. Goopalkrishnan

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor
Plot No. C/1, G Block
Bandra-Kurla Complex
Bandra – (East)
Mumbai – 400 051

Kind Attn.: Famroze Pochara
Asst. Vice President

Ahmedabad Stock Exchange Limited
Kamdhenu Complex
Opp. Sahajanand College
Panjara Pole,
Ahmedabad – 380 015

Dear Sir

Re.: Press Release

We are forwarding you herewith copy of press release proposed to be published in the newspapers in the matter of unaudited financial results for the quarter/half-year ended on September 30, 2014 the same may please receive in order.

Thanking you

Yours faithfully

For **CADILA HEALTHCARE LIMITED**



UPEN H. SHAH
COMPANY SECRETARY

Encl.: As above

Zydus Cadila's Net Profit up by 52% in Q2

Ahmedabad, November 6, 2014

For the second quarter ended September 30, 2014, Zydus Cadila reported Total Operating Income of Rs. 2,108 crores, up by 21% from Rs. 1747 crores in the corresponding quarter of the previous year on a consolidated basis. Net Profit for the same period was up by 52% from Rs. 183 crores to 278 crores.

During the quarter, the company's business in the US posted sales of Rs. 802 crores registering a growth of 68%. The company received approval for 6 new products from the USFDA and 4 products were launched in the US market.

In the domestic formulations market, the company launched 16 new products, including line extensions, of which 6 products were the first to be launched in India. In Mexico, the company launched 2 new products during the quarter, taking the cumulative launches to 12 and received the regulatory approval for 2 more dossiers, taking the cumulative number of approvals to 17.

During the quarter, the company entered into a non-exclusive licensing agreement with Gilead Sciences, Inc. which will allow the generic manufacture of sofosbuvir and the investigational single tablet regimen of ledipasvir/sofosbuvir for distribution in 90 developing countries, including India. There are nearly 10 million patients suffering from hepatitis C in India. The problem is further compounded by the fact that patients remain undiagnosed till the late stage and can ill afford the treatment.
